Keros Therapeutics (NASDAQ:KROS) Reaches New 12-Month Low – Should You Sell?

Keros Therapeutics, Inc. (NASDAQ:KROS) shares hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $15.18 and last traded at $15.18, with a volume of 167623 shares changing hands. The stock had previously closed at $15.84.

Analysts Set New Price Targets

Several brokerages recently weighed in on KROS. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating on the stock. Bank of America cut their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Truist Financial cut their price target on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, December 23rd. Finally, William Blair downgraded shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $75.00.

Keros Therapeutics Price Performance

The firm has a market capitalization of $589.78 million, a PE ratio of -2.79 and a beta of 1.43. The company has a 50-day moving average price of $41.71 and a 200-day moving average price of $48.30.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same quarter last year, the business earned ($1.33) EPS. The firm’s revenue was up 4750.0% on a year-over-year basis. On average, research analysts predict that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

Institutional investors have recently modified their holdings of the company. Point72 Asset Management L.P. increased its stake in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after buying an additional 577,220 shares during the last quarter. Alkeon Capital Management LLC raised its position in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after purchasing an additional 298,694 shares during the period. Parkman Healthcare Partners LLC lifted its holdings in shares of Keros Therapeutics by 112.3% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock worth $24,493,000 after purchasing an additional 223,155 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Keros Therapeutics by 814.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock valued at $12,990,000 after purchasing an additional 199,245 shares during the period. Finally, FMR LLC grew its stake in Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after buying an additional 179,374 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.